IVIg prevents the in vitro activation of T cells by neutralizing the T cell activators

Immunology Letters

Volumn 150, Issue 1-2, 2013, Pages 54-60

  Padet, Lauriane ^a,b   Bazin, Renée ^a,b  

^a Héma Québec ^*  (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Anti CD3 CD28 beads; IVIg; Neutralization; T cell activation

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; HUMAN IMMUNOGLOBULIN;

ACCESSORY CELL; ANTIGEN EXPRESSION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, NEUTRALIZING; ANTIGENS, CD28; ANTIGENS, CD3; CELLS, CULTURED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; PROTEIN BINDING; T-LYMPHOCYTES;

EID: 84874542530     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.12.011     Document Type: Article

References (38)

1. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, 1:1228-1231.
2. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
3. Arnson Y., Shoenfeld Y., Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009, 42:553-560.
4. Hughes R.A., Dalakas M.C., Cornblath D.R., Latov N., Weksler M.E., Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009, 158(Suppl. 1):34-42.
5. Hartung H.P., Mouthon L., Ahmed R., Jordan S., Laupland K.B., Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol 2009, 158(Suppl. 1):23-33.
6. Lemieux R., Bazin R., Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005, 42:839-848.
7. Negi V.S., Elluru S., Siberil S., Graff-Dubois S., Mouthon L., Kazatchkine M.D., et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007, 27:233-245.
8. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011, 127:315-323. quiz 324-325.
9. Charlton B., Lafferty K.J. The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 1995, 7:793-798.
10. Kroemer G., Hirsch F., Gonzalez-Garcia A., Martinez C. Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Autoimmunity 1996, 24:25-33.
11. O'Garra A., Steinman L., Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997, 9:872-883.
12. Lafaille J.J. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev 1998, 9:139-151.
13. Abbas A.K., Lohr J., Knoechel B., Nagabhushanam V. T cell tolerance and autoimmunity. Autoimmun Rev 2004, 3:471-475.
14. Crane I.J., Forrester J.V. Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005, 25:75-102.
15. King C., Tangye S.G., Mackay C.R. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008, 26:741-766.
16. Tsubakio T., Kurata Y., Katagiri S., Kanakura Y., Tamaki T., Kuyama J., et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983, 53:697-702.
17. Dammacco F., Iodice G., Campobasso N. Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Haematol 1986, 62:125-135.
18. Mouzaki A., Theodoropoulou M., Gianakopoulos I., Vlaha V., Kyrtsonis M.C., Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002, 100:1774-1779.
19. Aktas O., Zipp F. Regulation of self-reactive T cells by human immunoglobulins - implications for multiple sclerosis therapy. Curr Pharm Des 2003, 9:245-256.
20. Yamada H., Morikawa M., Furuta I., Kato E.H., Shimada S., Iwabuchi K., et al. Intravenous immunoglobulin treatment in women with recurrent abortions: increased cytokine levels and reduced Th1/Th2 lymphocyte ratio in peripheral blood. Am J Reprod Immunol 2003, 49:84-89.
21. Maddur M.S., Othy S., Hegde P., Vani J., Lacroix-Desmazes S., Bayry J., et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol 2010, 30(Suppl. 1):S4-S8.
22. Knezevic-Maramica I., Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion (Paris) 2003, 43:1460-1480.
23. Klaesson S., Ringden O., Markling L., Remberger M., Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993, 38:477-484.
24. Tha-In T., Metselaar H.J., Tilanus H.W., Boor P.P., Mancham S., Kuipers E.J., et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 2006, 81:1725-1734.
25. MacMillan H.F., Lee T., Issekutz A.C. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. Clin Immunol 2009, 132:222-233.
26. Tawfik D.S., Cowan K.R., Walsh A.M., Hamilton W.S., Goldman F.D. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production. Pediatr Allergy Immunol 2012, 23:88-95.
27. Achiron A., Margalit R., Hershkoviz R., Markovits D., Reshef T., Melamed E., et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 1994, 93:600-605.
28. Skansen-Saphir U., Andersson J., Bjork L., Ekberg C., Fehniger T.E., Henter J.I., et al. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol 1998, 47:229-235.
29. Aubin E., Lemieux R., Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010, 115:1727-1734.
30. Padet L., St-Amour I., Aubin E., Bazin R. Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?. Clin Exp Immunol 2011, 166:352-360.
31. Munson M.E. An improved technique for calculating relative response in cellular proliferation experiments. Cytometry A 2010, 77:909-910.
32. Perosa F., Rizzi R., Pulpito V., Dammacco F. Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific?. Clin Exp Immunol 1995, 99:16-20.
33. Amran D., Renz H., Lack G., Bradley K., Gelfand E.W. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994, 73:180-186.
34. Umetsu D.T., Katzen D., Chatila T., Miller R., Jabara H.H., Maher M., et al. Requirements for activation of human peripheral blood T cells by mouse monoclonal antibodies to CD3. Clin Immunol Immunopathol 1987, 43:48-64.
35. Verwilghen J., Baroja M.L., Van Vaeck F., Van Damme J., Ceuppens J.L. Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation. Immunology 1991, 72:269-276.
36. Williams J.M., Deloria D., Hansen J.A., Dinarello C.A., Loertscher R., Shapiro H.M., et al. The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol 1985, 135:2249-2255.
37. Paquin Proulx D., Aubin E., Lemieux R., Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol 2010, 135:422-429.
38. Barcy S., Wettendorff M., Leo O., Urbain J., Kruger M., Ceuppens J.L., et al. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Int Immunol 1995, 7:179-189.